Wainwright Associates merges with YES Pharma Services

Published: 17-Aug-2015
Regulatory

UK firm is committed to excellence in regulatory affairs and pharmacovigilance


Wainwright Associates, a UK-based consultancy specialising in EU regulatory affairs and pharmacovigilance, has merged with YES Pharma Services (YES), a knowledge-based service provider in the pharmaceutical, medical device and cosmetics sector based in Friedrichsdorf, Germany.

Founded in January 1999 by Dr Chris Wainwright and Penelope Wainwright, Wainwright Associates has grown organically, resulting from a mix of client referrals and repeat business. The company now employs more than 30 people.

The founders say the decision to combine forces with YES reinforces their belief that a larger organisation will allow the company to offer a wider range of services in a multinational arena.

YES has acquired all of the share capital of Wainwright Associates.

Since its establishment in 1994 by Dr Markus Zimmer and Dr Thomas Dobmeyer, YES has grown steadily and now employs around 200 people in Germany, US, Brazil, India and Spain.

YES is an owner-managed company and one of the biggest and best-known European service companies in the area of drug development, regulatory affairs and drug safety.

Chris and Penelope Wainwright say: 'YES shares the same values as we do and is committed to providing high quality consulting services that exceed client expectations.

'Together we will continue the tradition of excellent service and a high standard of expertise in an environment our clients will want to share. We will be able to provide our clients with many new services and areas of expertise in the future.

'Together with YES we will offer a wider range of options in consulting, processing and support services – from drug development and registration through to product maintenance.'

  • Companies:
  • PharmaLex
  • YES Pharma Services
See more

You may also like

Regulatory

The right validation model: practical considerations and applications

Read more
It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  3. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

The right validation model: practical considerations and applications

It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
Regulatory

European Commission adopts proposal to delay MDR deadlines

With thousands of outstanding conformity assessments for medical device certification under the Medical Device Regulation and limited capacity to manage these within the transition period, concerns about widespread product shortages in the EU market have been growing
Regulatory

Investment, outsourcing and globalisation: key trends for 2023

The start of 2023 has been challenging for the pharmaceutical industry. Economic constraints in Europe and the United States, staffing shortages, an increasingly complex regulatory environment and heightened competition for funding is putting pressure on companies
Regulatory

PharmaLex extends reach in Asia with Ascent merger

Headquartered in Tokyo, Ascent employs staff across Asia, and provides country-specific knowledge mixed with strategic advice from a global perspective
Regulatory

PharmaLex taps DocShifter for PDF generation

DocShifter is a document conversion and validation solution for pharmaceutical, biotech and medical device companies
Regulatory

Why Bayesian statistics is revolutionising pharmaceutical decision making

PharmaLex's Bruno Boulanger, Global Head of Statistics and Data Science, and Brad Carlin, Senior Adviser for Statistics and Data Science, explore the growing significance of Bayesian statistics in supporting decision-making across the development and regulatory processes and its potential to improve outcomes for the biopharmaceutical industry
Regulatory

EFSA declares titanium dioxide unsafe for food products

Thomas Eberwein, Head of Pharmaceutical Quality at Pharmalex, explains the EFSA’s recent decision to declare titanium dioxide unsafe for food products, and the implications for manufacturers
Subscribe now